Document text
Principal Investigator: Sonya Reid
Organization: RHODE ISLAND HOSPITAL
Fiscal Year: 2024
Award: $732,687
Funding agency: National Cancer Institute
Project Summary
People with cancer have a higher risk of infections in general because of vulnerabilities arising
from their cancer and its treatments. This is especially true for the novel coronavirus, SARS-CoV-
2. People with cancer are twice as likely to die from COVID-19 compared to the general
population, with some subgroups appearing to fare much worse. The pandemic has also led to
significant disruption in cancer screening, diagnosis, and treatment, which is anticipated to lead
to an indirect increase in morbidity and mortality in this population. Thus, studying COVID-19 in
people with cancer is highly warranted. In this U01 project, “The COVID-19 and Cancer
Consortium (CCC19) Registry”, we leverage the established CCC19 registry (NCT04354701),
which is the largest registry of adults with COVID-19 and cancer in North America, to answer a
number of important scientific questions. In Aim 1, we evaluate how anticancer treatments, anti-
COVID-19 treatments, vaccination, and, importantly, their interactions modify short- and long-
term complications. We will explore whether race, ethnicity, and sociodemographic factors (e.g.,
insurance, access to treatment) are associated with outcomes. We will explore whether data-
driven feature selection with machine-learning algorithms reveals unrecognized associations. In
Aim 2, we hypothesize that there will be measurable changes in cancer recurrence and
progression in patients who survive COVID-19. We will also investigate whether anticancer
treatment modifications, which we have observed in 40% of patients who were on anticancer
therapy at the time of infection, will affect longer-term prognosis. In Aim 3, we will develop
methods to measure ascertainment and collider biases, which are some of the most important
sources of bias in registry-based study designs. Along with these aims, we will continue to support
and maintain the CCC19 registry and promote its use by the general community, following the
FAIR principles.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><21+ years old><Access to Care><Acute><Adrenal Cortex Hormones><Adult><Adult Human><Advanced Cancer><Advanced Malignant Neoplasm><Affect><Biometrics><Biometry><Biostatistics><Bladder Cancer><CCOP><COVID crisis><COVID epidemic><COVID pandemic><COVID survivors><COVID-19><COVID-19 affected><COVID-19 consequence><COVID-19 crisis><COVID-19 effect><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 impact><COVID-19 impacted><COVID-19 infection><COVID-19 infection survivors><COVID-19 pandemic><COVID-19 period><COVID-19 predisposition><COVID-19 public health crisis><COVID-19 survivors><COVID-19 susceptibility><COVID-19 therapy><COVID-19 treatment><COVID-19 virus><COVID-19 virus infection><COVID-19 vulnerability><COVID-19 years><COVID19 infection><COVID19 virus><CV-19><Cancer Prognosis><Cancer Treatment><Cancers><Caring><Case Study><Cause of Death><Cervical Cancer><Cervix Cancer><Clinical><CoV emergence><CoV-2><CoV2><Communicable Diseases><Communities><Community Clinical Oncology Program><Community Oncology><Community Practice><Comprehensive Cancer Center><Coronavirus Infectious Disease 2019><Coronavirus disease 2019 predisposition><Coronavirus disease 2019 susceptibility><Coronavirus disease 2019 vulnerability><Corticoids><Corticosteroids><Data><Data Coordinating Center><Data Coordination Center><Decision Making><Dedications><Diagnosis><Disease><Disease remission><Disorder><Drugs><Enrollment><Ethnic Origin><Ethnicity><FAIR data><FAIR guiding principles><FAIR principles><Findable, Accessible, Interoperable and Re-usable><Findable, Accessible, Interoperable, and Reusable><General Population><General Public><Goals><Grawitz Tumor><Health Services Accessibility><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoietic Cancer><Heterogeneity><Histology><Hodgkin Disease><Hodgkin Disorder><Hodgkin lymphoma><Hodgkin's><Hodgkin's Lymphoma><Hodgkin's disease><Hodgkins lymphoma><Hospital Admission><Hospitalization><Hypernephroid Carcinoma><Hypernephroma><Immune mediated therapy><Immune system><Immunity><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunologically Directed Therapy><Immunosuppressed Host><Immunotherapy><Impairment><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Insurance><Investigators><JAK-2><JAK2><JAK2 gene><JAK2 protein><Janus kinase 2><Journals><Knowledge><Lead><Magazine><Malignant Bladder Neoplasm><Malignant Cell><Malignant Cervical Neoplasm><Malignant Cervical Tumor><Malignant Hematologic Neoplasm><Malignant Lymphogranuloma><Malignant Melanoma><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasm of the Cervix><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Bladder><Malignant Tumor of the Cervix><Malignant Tumor of the Cervix Uteri><Malignant Tumor of the Lung><Malignant Uterine Cervix Neoplasm><Malignant Uterine Cervix Tumor><Malignant neoplasm of cervix uteri><Malignant neoplasm of lung><Malignant neoplasm of urinary bladder><Measurable><Measures><Medication><Melanoma><Methods><Minority><Modification><Morbidity><Morbidity - disease rate><Nephroid Carcinoma><North America><Oncology><Oncology Cancer><Outcome><Patients><Pb element><Persons><Pharmaceutical Preparations><Population><Predisposed to COVID-19><Predisposed to SARS-CoV-2><Predisposed to Severe acute respiratory syndrome coronavirus 2><Primary Infection><Process><Prognosis><Publishing><Pulmonary Cancer><Pulmonary malignant Neoplasm><Quality Control><Race><Races><Recurrent Malignant Neoplasm><Recurrent Malignant Tumor><Registries><Remission><Renal Adenocarcinoma><Renal Cell Adenocarcinoma><Renal Cell Cancer><Renal Cell Carcinoma><Reporting><Research><Research Design><Research Personnel><Researchers><Risk Factors><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV-2 predisposition><SARS-CoV-2 survivors><SARS-CoV-2 susceptibility><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV-2 vulnerability><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Science><Screening for cancer><Secondary to><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 predisposition><Severe acute respiratory syndrome coronavirus 2 susceptibility><Severe acute respiratory syndrome coronavirus 2 vulnerability><Severe acute respiratory syndrome related corona virus 2><Site><Source><Study Type><Subgroup><Time><Tyrosine-Protein Kinase JAK2><Underrepresented Groups><Underrepresented Populations><United States><Urinary Bladder Cancer><Urinary Bladder Malignant Tumor><Uterine Cervix Cancer><Vaccination><Viral Respiratory Tract Infection><Wuhan coronavirus><access to health services><access to services><access to treatment><accessibility to health services><adulthood><anti-cancer therapy><anti-cancer treatment><availability of services><cancer care><cancer cell><cancer diagnosis><cancer progression><cancer recurrence><cancer therapy><cancer-directed therapy><care access><case report><cohort><corona virus emergence><coronavirus disease 2019><coronavirus disease 2019 consequence><coronavirus disease 2019 crisis><coronavirus disease 2019 effect><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 impact><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 impact><coronavirus disease-19 pandemic><coronavirus disease-19 virus><coronavirus emergence><coronavirus infectious disease-19><data management and coordinating center><data management center><drug/agent><early cancer detection><emergent CoV><emergent corona virus><emergent coronavirus><emerging CoV><emerging corona virus><emerging coronavirus><end of life><end-of-life><enroll><esophagogastric cancer><experience><feature selection><future pandemic><gastroesophageal cancer><hCoV19><health service access><health services availability><heavy metal Pb><heavy metal lead><high risk><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunosuppressed patient><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><infection risk><inhibitor><kidney adenocarcinoma><lung cancer><machine learned algorithm><machine learning algorithm><machine learning based algorithm><malignancy><meeting><meetings><mortality><nCoV><nCoV2><neoplasm progression><neoplasm/cancer><neoplastic progression><new CoV><new corona virus><new coronavirus><next pandemic><novel CoV><novel corona virus><novel coronavirus><operation><operations><pandemic><pandemic disease><predisposed to Coronavirus disease 2019><programs><racial><racial background><racial origin><recruit><response><screening cancer patients><service availability><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><socio-demographic factors><sociodemographic factors><study design><survive COVID-19><survive SARS-CoV-2><susceptible to COVID-19><susceptible to Coronavirus disease 2019><susceptible to SARS-CoV-2><susceptible to Severe acute respiratory syndrome coronavirus 2><treat COVID-19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><treatment access><tumor progression><under representation of groups><under represented groups><under represented people><under represented populations><under served community><underrepresentation of groups><underrepresented people><underserved community><viral respiratory infection><vulnerable to COVID-19><vulnerable to Coronavirus disease 2019><vulnerable to SARS-CoV-2><vulnerable to Severe acute respiratory syndrome coronavirus 2>